Freeline Therapeutics Holdings plc (FRLN)
After hours:
| Previous close | 0.6400 |
| Open | 0.6304 |
| Bid | 0.6111 x 900 |
| Ask | 0.0000 x 1000 |
| Day's range | 0.6111 - 0.6640 |
| 52-week range | 0.6000 - 2.7500 |
| Volume | |
| Avg. volume | 24,738 |
| Market cap | 43.098M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizing development of FLT201 in Gaucher disease and FLT190 in Fabry disease; ceasing investment in further development of FLT180a in hemophilia B Updated data from first cohort of MARVEL-1 trial show FLT190 continues to be well-toler
- Globe Newswire
Freeline to Present at the Stifel Healthcare Conference
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York. The fireside chat will take place on November 16th at 8:35 am ET. Senior management will also participate in one-on-one investor meetings during the conference. A live webcast of the fireside chat will be available on the Investors section of Freeline’
- Globe Newswire
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration
